Effects of risedronate versus menopausal hormone therapy on bone mineral density in postmenopausal Korean women with hip fracture: a randomized, open-label trial

Maturitas ◽  
2019 ◽  
Vol 124 ◽  
pp. 143
Author(s):  
Hyun Hye Lim ◽  
Seung Jae Lim ◽  
Youn Soo Park ◽  
Sang Hee Choi ◽  
Yong Ki Min ◽  
...  
Author(s):  
Yong-Ki Min ◽  
Dong-Yun Lee ◽  
Suk-Joo Choi ◽  
Joo Han Kim ◽  
DooSeok Choi ◽  
...  

ASJ. ◽  
2021 ◽  
Vol 1 (56) ◽  
pp. 28-33
Author(s):  
O. Kalinkina ◽  
Yu. Tezikov ◽  
I. Lipatov

87 patients aged 40-69 years in the period of pre- and postmenopause were examined. In the analysis of age-related dynamics of bone mineral density (BMD) It was found that densitometry indicators corresponding to osteoporosis directly correlate with age and duration of the postmenopausal period. It is advisable in women of this age group with a decrease in bone mineral density, the combined appointment of menopausal hormone therapy (MGT) and non-hormonal therapy affecting bone metabolism (calcitonin). For the purpose of MGT in premenopausal women, the use of femostone 2/10 is effective, in postmenopausal women - femostone 1/10 and femostone 1/5, which does not cause withdrawal bleeding. If there are contraindications to menopausal hormone therapy, the prevention and treatment of osteoporosis should be guided by the appointment of nonhormonal drugs, in particular, calcitonin.


2009 ◽  
Vol 14 (3) ◽  
pp. 208-213
Author(s):  
Yoon-Jin Shin ◽  
In-Sook Kwun ◽  
Young-Jun Woon ◽  
Yang-Ha Kim

Sign in / Sign up

Export Citation Format

Share Document